First Turn Management LLC Cuts Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

First Turn Management LLC decreased its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 66.5% in the third quarter, HoldingsChannel reports. The firm owned 355,000 shares of the specialty pharmaceutical company’s stock after selling 704,540 shares during the quarter. First Turn Management LLC’s holdings in KalVista Pharmaceuticals were worth $4,111,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in KALV. Capital World Investors purchased a new position in shares of KalVista Pharmaceuticals during the first quarter valued at about $17,370,000. Great Point Partners LLC purchased a new position in KalVista Pharmaceuticals in the second quarter worth about $15,768,000. StemPoint Capital LP grew its position in KalVista Pharmaceuticals by 174.4% in the first quarter. StemPoint Capital LP now owns 1,161,060 shares of the specialty pharmaceutical company’s stock worth $13,770,000 after acquiring an additional 737,886 shares in the last quarter. Emerald Advisers LLC grew its position in KalVista Pharmaceuticals by 29.8% in the third quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock worth $9,681,000 after acquiring an additional 192,091 shares in the last quarter. Finally, Emerald Mutual Fund Advisers Trust grew its position in KalVista Pharmaceuticals by 23.0% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 650,980 shares of the specialty pharmaceutical company’s stock worth $7,538,000 after acquiring an additional 121,615 shares in the last quarter.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ KALV opened at $9.30 on Tuesday. The company has a market cap of $401.90 million, a P/E ratio of -2.63 and a beta of 0.92. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.39 and a 1 year high of $16.88. The firm has a 50-day simple moving average of $11.14 and a two-hundred day simple moving average of $12.05.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings data on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.91) by $0.04. As a group, equities research analysts expect that KalVista Pharmaceuticals, Inc. will post -2.7 EPS for the current year.

Insider Activity

In related news, CEO Benjamin L. Palleiko sold 7,352 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $12.19, for a total transaction of $89,620.88. Following the transaction, the chief executive officer now directly owns 250,800 shares of the company’s stock, valued at $3,057,252. This trade represents a 2.85 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Paul K. Audhya sold 2,135 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $12.40, for a total transaction of $26,474.00. Following the transaction, the insider now directly owns 83,745 shares in the company, valued at approximately $1,038,438. The trade was a 2.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 10.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Monday, October 7th. Needham & Company LLC reiterated a “buy” rating and issued a $32.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, September 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, September 9th.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).